Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction.
about
Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine.Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertensionRGS4, a GTPase activator, improves renal function in ischemia-reperfusion injury.Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.High levels of placenta growth factor in sickle cell disease promote pulmonary hypertensionHeme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factorEvidence for the endothelin system as an emerging therapeutic target for the treatment of chronic painModulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilationCirculating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease.Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.Antisickling fetal hemoglobin reduces hypoxia-inducible factor-1α expression in normoxic sickle mice: microvascular implications.Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen speciesNovel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.Atherosclerosis in sickle cell disease - a review.Peroxisome Proliferator-Activated Receptor γ Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung.Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia.Placenta growth factor mediated gene regulation in sickle cell disease.Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain.Efficacy of homologous inositol hexaphosphate-loaded red blood cells in sickle transgenic mice.Endothelin-Type A receptors mediate pain in a mouse model of sickle cell disease.Endothelin-A Receptor Antagonism Retards the Progression of Murine Sickle Cell Nephropathy.
P2860
Q33803027-F510AD53-D171-43D3-B833-23650861C22AQ33806253-83F29F6A-918E-4162-BAAC-F0F27A7F37E4Q33848879-79815E92-1665-4EC3-95FB-A62B810E73F6Q33899415-2E52556A-9654-4229-A3B7-7EEE7166356FQ33997180-E9068FBE-CED8-447A-A215-82902385B663Q34019609-22BB4446-9E48-49DA-AD14-28883559D6E0Q34140692-049F4FD2-07C9-47C5-A3E3-1FF1D5ABDB06Q34979534-3A9D5FCF-76B2-4B4F-B913-3F0AB1D7C1B0Q35813199-D95DC8DA-D65E-4A8B-9C68-49C994861074Q35849493-1D11E11D-5F1F-4A20-89E2-885AD8F99A9DQ36088594-D33C7828-FA0B-4211-8B06-F2337BCB16E8Q36419650-A3C350B3-293E-4CB0-BD8E-B733A31D9043Q36528107-81665B61-9D64-46D9-99C8-2A0ACC3AC60DQ37084544-A60D40DE-CEB6-4B23-A670-1E687765B63EQ37346719-260A63DF-25CD-4BEE-B60B-25E75A4A0971Q37565002-3ADC748A-F410-4FEA-A29D-F2EBE547735EQ38000155-0EEBD1D3-1070-4B8F-A3A9-04D912887C34Q40588101-4CADD5C0-B4ED-41F8-A723-4A7BD2F2CE94Q41975944-58A334DD-7D51-498C-AFF6-ECEC281E3E2EQ46063095-2426FDCC-FE9E-40FA-9973-B20CC52111C7Q46321267-8454CB11-411F-4259-B9F4-46E4D8269D6EQ48621899-7AA34BD4-08AD-469F-A8E6-DCE58F735D2AQ52653304-5F800E11-38C2-4348-B482-322080E4E015Q52775082-BDFFD48E-0E55-4F96-9BFE-27016C92A845
P2860
Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Vasoactive factors in sickle c ...... n-1-mediated vasoconstriction.
@en
Vasoactive factors in sickle c ...... n-1-mediated vasoconstriction.
@nl
type
label
Vasoactive factors in sickle c ...... n-1-mediated vasoconstriction.
@en
Vasoactive factors in sickle c ...... n-1-mediated vasoconstriction.
@nl
prefLabel
Vasoactive factors in sickle c ...... n-1-mediated vasoconstriction.
@en
Vasoactive factors in sickle c ...... n-1-mediated vasoconstriction.
@nl
P2093
P2860
P356
P1476
Vasoactive factors in sickle c ...... n-1-mediated vasoconstriction.
@en
P2093
Abdullah Kutlar
Adviye Ergul
Chris Y Brunson
Jim Hutchinson
R Clinton Webb
Sitki Ergul
P2860
P304
P356
10.1002/AJH.20107
P50
P577
2004-07-01T00:00:00Z